A Placebo-Controlled, Double-Blind, Randomized, Multi-Center Study to Assess the Effects of Dronedarone 400 mg BID for 12 Weeks on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers.

Trial Profile

A Placebo-Controlled, Double-Blind, Randomized, Multi-Center Study to Assess the Effects of Dronedarone 400 mg BID for 12 Weeks on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2013

At a glance

  • Drugs Dronedarone (Primary)
  • Indications Atrial fibrillation; Atrial flutter
  • Focus Therapeutic Use
  • Acronyms HESTIA
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.
    • 06 Nov 2012 Primary endpoint 'Incidence-of-atrial-fibrillation' has been met.
    • 20 Mar 2012 Actual patient number is 112 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top